CD Bioparticles Introduces Comprehensive Solutions for Exosome DNA & RNA Isolation

January 17, 2025 01:32 PM AEDT | By EIN Presswire
 CD Bioparticles Introduces Comprehensive Solutions for Exosome DNA & RNA Isolation
Image source: EIN Presswire

CD Bioparticles announces its comprehensive portfolio of products for the isolation and extraction of Exosome DNA & RNA. NEW YORK, NY, UNITED STATES, January 16, 2025 /EINPresswire.com/ -- CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, announces its comprehensive portfolio of products for the isolation and extraction of Exosome DNA & RNA. These advanced kits are designed to streamline research into exosomes, offering researchers efficient and reliable tools for analyzing these crucial nanoscale vesicles.

Exosomes are extracellular membrane vesicles (EVs) with a diameter of 30-200 nm secreted by various cells. Exosomes are commonly found in a variety of body fluids and their contents are rich in proteins, lipids and nucleic acids. They play an important role in intercellular information exchange, mainly involved in immune antigen presentation, neurotransmitter transmission, lipid metabolism and cell signalling, and are closely associated with the onset, development, treatment and prognosis of many diseases.

In recent years, liquid biopsy, as a new non-invasive method, mainly detects circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) in the blood, provides information about patients' tumour lesions and is used to aid in the diagnosis and treatment of the disease. In addition, studies have now shown that genomic DNA and mitochondrial DNA can be detected in exosomes. As a novel drug delivery vehicle with natural properties, exosomes have the ability to cross the biological barrier of the human body and deliver drugs effectively and safely, making them a feasible and effective method of treating diseases.

Analyzing Exosome DNA & RNA has become increasingly important in various research fields, including cancer diagnostics, drug delivery, and personalized medicine. To better study the exosomal DNA, CD Bioparticles has developed a comprehensive portfolio of Exosome Extraction and DNA Isolation Kits, which can easily and quickly isolate exosomal DNA from serum or plasma that is not contaminated with other DNA. These kits can be used to isolate exosomes from cell culture supernatants or body fluids (serum/plasma, etc.).

The main principle of these kits is the design and modification of resins that specifically bind to exosomes based on the membrane structure of exosomes (lipid bilayer), thus enabling the extraction and purification of exosomes by binding to components of the exosome lipid bilayer with little or no binding to other proteins in the sample. Exosome DNA can be easily and rapidly purified and eluted using the spin column method and can be used directly in downstream applications such as real-time PCR, expression array assays, and NGS.

CD Bioparticles is dedicated to providing researchers with the highest quality tools to advance the field of drug delivery. Its comprehensive portfolio of Exosome DNA & RNA isolation and extraction kits empowers researchers to unlock the full potential of exosome research. To find out more information about CD Bioparticles' Exosome DNA & RNA solutions, please visit https://www.cd-bioparticles.net/products/exosome-dna-rna.

About CD Bioparticles

CD Bioparticles is an established drug delivery company that provides customized solutions for developing and manufacturing novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles for drug delivery. The company also provides contract research services for drug delivery formulation, formulation feasibility study, process development and scale-up, as well as analytical and non-clinical research services.

Richard J. Gray
CD Bioparticles
email us here
Visit us on social media:
Facebook
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.